Pyxis Oncology files pro forma financials for Apexigen acquisition; combined net loss $97.8M

Pyxis Oncology, Inc.

Pro forma combined net loss for FY 2023: $97.8M (basic EPS $2.29).
Purchase price for Apexigen: $10.7M, comprising 4.3M Pyxis shares at $2.295/share.
Intangible assets acquired: $24.5M (IPR&D $21.0M, royalty rights $3.5M).
Nonrecurring transaction costs included: $1.7M in Pyxis G&A, $5.5M in Apexigen G&A.
Severance costs of $4.7M recorded: $1.6M G&A, $3.1M R&D.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.